Clinical Trial Update: to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating MG4101, an ex vivo expanded allogeneic natural killer (NK) cell therapy, for hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• MG4101 (ex vivo expanded allogeneic NK cell therapy)

Snippet

Sponsor: Samsung Medical Center | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED